Cancer

Cancer and telomeres - An alternative to telomerase

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Finding ways to target the alternative (ALT) telomere lengthening pathway found in some cancer cells could complement telomerase inhibitors currently in clinical trials.

Original languageEnglish (US)
Pages (from-to)1388-1390
Number of pages3
JournalScience
Volume336
Issue number6087
DOIs
StatePublished - Jun 15 2012

Fingerprint

Complement Inactivating Agents
Telomere Homeostasis
Telomerase
Telomere
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

Cancer : Cancer and telomeres - An alternative to telomerase. / Shay, Jerry W.; Reddel, Roger R.; Wright, Woodring E.

In: Science, Vol. 336, No. 6087, 15.06.2012, p. 1388-1390.

Research output: Contribution to journalArticle

Shay, Jerry W. ; Reddel, Roger R. ; Wright, Woodring E. / Cancer : Cancer and telomeres - An alternative to telomerase. In: Science. 2012 ; Vol. 336, No. 6087. pp. 1388-1390.
@article{335b5ba8476947e8bf973705d8bdf663,
title = "Cancer: Cancer and telomeres - An alternative to telomerase",
abstract = "Finding ways to target the alternative (ALT) telomere lengthening pathway found in some cancer cells could complement telomerase inhibitors currently in clinical trials.",
author = "Shay, {Jerry W.} and Reddel, {Roger R.} and Wright, {Woodring E.}",
year = "2012",
month = "6",
day = "15",
doi = "10.1126/science.1222394",
language = "English (US)",
volume = "336",
pages = "1388--1390",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6087",

}

TY - JOUR

T1 - Cancer

T2 - Cancer and telomeres - An alternative to telomerase

AU - Shay, Jerry W.

AU - Reddel, Roger R.

AU - Wright, Woodring E.

PY - 2012/6/15

Y1 - 2012/6/15

N2 - Finding ways to target the alternative (ALT) telomere lengthening pathway found in some cancer cells could complement telomerase inhibitors currently in clinical trials.

AB - Finding ways to target the alternative (ALT) telomere lengthening pathway found in some cancer cells could complement telomerase inhibitors currently in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84862288783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862288783&partnerID=8YFLogxK

U2 - 10.1126/science.1222394

DO - 10.1126/science.1222394

M3 - Article

VL - 336

SP - 1388

EP - 1390

JO - Science

JF - Science

SN - 0036-8075

IS - 6087

ER -